OOIR: Observatory of International Research

Papers

(The H4-Index of npj Parkinsons Disease is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease	208
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism	124
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	122
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease	115
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	108
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	98
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome	98
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease	97
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	96
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	94
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	92
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	91
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	90
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein	85
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	79
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective	78
Differences in brain aging between sexes in Parkinson’s disease	77
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	70
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease	66
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	65
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study	65
Redefining the hypotheses driving Parkinson’s diseases research	63
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	62
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	61
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	61

α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission	61
Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research	61
A versatile computational algorithm for time-series data analysis and machine-learning models	60
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population	60
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease	58
The experience of Anxiety for people with Parkinson’s disease	57
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	57
Advanced brain aging in Parkinson’s disease with cognitive impairment	56
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	55
Baseline [18F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson’s disease	53
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism	53
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia	52
Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism	52
Parkinson’s disease clinical milestones and mortality	52
A systematic review and meta-analysis of the prevalence of Parkinson’s disease in lower to upper-middle-income countries	52
Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach	50
Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus	50
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	49
Synuclein phosphorylation: pathogenic or physiologic?	48
Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder	48
In memorium, Michael Zigmond, PhD	48
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus	47